Wellness Nomad | Alternative Medicine Specialist
Earlier this year, a spa director at a Southeast Asian wellness destination sent me a proposed treatment menu for review.
Halfway down the page, between the massage rituals and the facial protocols, sat a new category. Peptide therapy. Topical and injectable. Anti-ageing, recovery, longevity.
I asked where the protocols had come from. A supplier had presented them. The evidence pack was a brochure. The training was a webinar.
The director was not careless. She is one of the most conscientious operators I have worked with. She was doing what the industry around her was doing.
The evidence pack was a brochure. The training was a webinar.
The industry that arrived overnight
Peptides have moved faster than almost any category I have watched in sixteen years of spa and wellness work.
In July, an ABC Four Corners investigation identified roughly one hundred longevity and wellness operators that have opened in Australia in the last few years, telehealth and bricks-and-mortar, selling injections that promise youth, energy, and repair. In one case documented by the programme, a doctor prescribed a stack of them after a short questionnaire and a phone call.
The compounds carry laboratory names. BPC-157. CJC-1295. TB-500. None has been shown to deliver its claimed effects in humans. Australia’s medicines regulator has now named unapproved peptides a priority enforcement area.
So I did what I do before any modality goes near a menu I am responsible for. I went to the clinical literature.
A 2026 systematic review and meta-analysis indexed on PubMed: nineteen randomised controlled trials, 1,341 participants, found a modest pooled effect on skin ageing, driven mostly by oral supplements, and its authors state plainly that larger trials with standardised outcomes are still needed. Reviews of topical cosmetic peptides describe the evidence as supportive but modest, and note that many of these molecules struggle to penetrate the skin at all.
That is the strongest honest version of the case. Modest, early, unresolved. The menus being written right now say something very different.
What the gap costs
When Four Corners had black-market peptide samples tested in an accredited laboratory, the vials contained varying amounts of the advertised compound.
One contained none of it at all.
One tested vial contained none of the advertised peptide at all.
The regulator has recorded cases of acute liver toxicity linked to an unapproved weight-loss peptide. Health officials report hospitalisations. Testing of enhancement products has found contamination with lead, arsenic, and cadmium.
For a luxury property the exposure is threefold. Guest safety, first and always. Legal liability, because advertising or supplying unapproved peptides is unlawful in several of the markets where luxury wellness operates. And credibility, which in this segment is not a soft asset. It is the product.
I want to be equally precise about what I am not saying. Peptides are not pseudoscience. They are real molecules doing real work — insulin is a peptide, and the GLP-1 medicines reshaping metabolic health are peptides, rigorously trialled and approved. Some topical cosmetic peptides show genuinely promising early results. The molecule is not the problem.
My concern is the gap. The distance between what has been demonstrated and what is being sold, and the speed at which that distance is being monetised.
A treatment menu is a clinical document
Somewhere along the way the industry started treating the spa menu as marketing collateral. It is not. It is a set of claims a property makes about outcomes in the body of a guest.
Every modality on a menu should answer three questions. What is the evidence, stated at its honest strength. Who administers this, and what is their training provenance. And what happens when something goes wrong.
A brochure answers none of them.
Why I am telling you this
Because the decision point for peptides is not in the treatment room. It is in the GM’s office and the owner’s boardroom, where menus get approved by people who were never given the tools to interrogate a supplier’s evidence pack.
That knowledge gap at leadership level is the single biggest vulnerability in luxury wellness today. It is how trend-following gets mistaken for innovation. And it is precisely where clinical governance belongs — built into the property the way fire safety is, not bolted on after an incident.
Guests come to a wellness destination for one thing before anything else. To feel safe enough to let go. A menu that has outrun its own evidence breaks that promise at the level of the institution, quietly, before a single treatment is delivered.
In your property, if a guest asked tomorrow for the evidence behind any single treatment on your menu, who in the building could answer them?
Update — 27 August 2026
Since this piece went up, the picture has moved. Seven Victorian patients have now been hospitalised with acute liver toxicity after taking an unapproved peptide sold as retatrutide, a weight-loss compound. One became seriously unwell within weeks, after a second dose. The Therapeutic Goods Administration and Australian Border Force have destroyed more than 94,500 unapproved peptide products this year.
The treating hepatologist, Dr Marie Sinclair, has commissioned testing of counterfeit samples and is careful about how far the evidence currently reaches, describing the contaminated-batch explanation as “purely a hypothesis at this stage”. The regulator’s Robyn Langham has said the localised nature of the Victorian cases points to a batch problem.
I am repeating that caution deliberately. A contaminated batch is a hypothesis, not a finding, and the discipline of saying so is the entire argument of this article. What is not hypothetical is the number of people in hospital.
If you are reviewing a menu, opening a property, or being shown a category you cannot yet evaluate, the consulting and advisory work is where that conversation begins.
A version of this article first appeared on LinkedIn. Nothing here is medical advice.
Sources: ABC Four Corners — The Race to Reverse Aging; Therapeutic Goods Administration — compliance focus on unapproved peptide products; Nukaly et al., Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials, Frontiers in Medicine, 2026.